1,400,000 Shares in Dynavax Technologies Corporation (DVAX) Acquired by PointState Capital LP
PointState Capital LP purchased a new position in Dynavax Technologies Corporation (NASDAQ:DVAX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,400,000 shares of the biopharmaceutical company’s stock, valued at approximately $13,510,000. PointState Capital LP owned about 2.56% of Dynavax Technologies Corporation as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of DVAX. GMT Capital Corp grew its stake in shares of Dynavax Technologies Corporation by 231.5% in the 1st quarter. GMT Capital Corp now owns 2,344,500 shares of the biopharmaceutical company’s stock worth $13,950,000 after buying an additional 1,637,300 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Dynavax Technologies Corporation in the 1st quarter worth approximately $4,323,000. Candriam Luxembourg S.C.A. purchased a new stake in shares of Dynavax Technologies Corporation in the 2nd quarter worth approximately $5,066,000. Bain Capital Public Equity Management LLC purchased a new stake in shares of Dynavax Technologies Corporation in the 2nd quarter worth approximately $4,741,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Dynavax Technologies Corporation by 344.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 505,227 shares of the biopharmaceutical company’s stock worth $4,876,000 after buying an additional 391,632 shares during the last quarter. Institutional investors own 60.20% of the company’s stock.
Dynavax Technologies Corporation (NASDAQ:DVAX) traded down 4.05% during mid-day trading on Friday, hitting $23.10. The company had a trading volume of 1,653,228 shares. The firm’s market capitalization is $1.26 billion. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $24.45. The company has a 50 day moving average of $19.78 and a 200 day moving average of $11.22.
Dynavax Technologies Corporation (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. During the same period in the previous year, the company earned ($0.75) earnings per share. Analysts predict that Dynavax Technologies Corporation will post ($1.63) earnings per share for the current fiscal year.
Several analysts recently weighed in on DVAX shares. Zacks Investment Research upgraded Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Monday, July 10th. Royal Bank Of Canada set a $7.00 price target on Dynavax Technologies Corporation and gave the stock a “hold” rating in a research note on Wednesday, July 26th. William Blair restated an “outperform” rating on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. Cowen and Company restated an “outperform” rating and issued a $45.00 price target on shares of Dynavax Technologies Corporation in a research note on Thursday, July 27th. Finally, J P Morgan Chase & Co upgraded Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $6.00 to $27.00 in a research note on Monday, July 31st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $25.00.
TRADEMARK VIOLATION NOTICE: “1,400,000 Shares in Dynavax Technologies Corporation (DVAX) Acquired by PointState Capital LP” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/10/07/1400000-shares-in-dynavax-technologies-corporation-dvax-acquired-by-pointstate-capital-lp.html.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Stock Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related stocks with our FREE daily email newsletter.